Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 28;12:658093. doi: 10.3389/fmicb.2021.658093

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Ji, Qin, Tao, Zhu, Liang, Zhou, Chen, Zhang, Yang, Duan and Jin.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The therapeutic effect of mAb treatment in the CVA2 infection mouse model. Five groups (n = 7 per group) of 5-day-old mice were inoculated i.m. with 10⁴ TCID₅₀/mouse of CVA2. After 12 h, mice were injected i.p. with Ultra-LEAF^TM purified neutralizing monoclonal anti-mouse IL-6 (1.33 mg/kg), TNF-α (50 mg/kg), and MCP-1 (10 mg/kg) IgG mAb. Suckling mice from the control group were injected with equivalent purified rat IgG1 (isotype control). The treated mice were observed daily for survival rates (A) and clinical scores (B) and there was no significant statistical difference compared with group CVA2 + Isotype control.